BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38059214)

  • 21. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Enoxaparin Associated With a Higher Risk of Persistent Wound Drainage Than Aspirin? A Secondary Analysis of Data From the CRISTAL Randomized Trial.
    Sidhu VS; Naylor JM; Adie S; Lieu D; Walker R; Horsley M; Kim RG; Harris IA
    Clin Orthop Relat Res; 2023 Jul; 481(7):1351-1359. PubMed ID: 36649465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Matharu GS; Kunutsor SK; Judge A; Blom AW; Whitehouse MR
    JAMA Intern Med; 2020 Mar; 180(3):376-384. PubMed ID: 32011647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal prophylaxis in patients with a history of venous thromboembolism undergoing primary elective hip arthroplasty.
    Gonzalez Della Valle A; Shanaghan KA; Nguyen J; Liu J; Memtsoudis S; Sharrock NE; Salvati EA
    Bone Joint J; 2020 Jul; 102-B(7_Supple_B):71-77. PubMed ID: 32600195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Revision Hip and Knee Arthroplasty as Reported by American Board of Orthopaedic Surgery Part II Candidates.
    Runner RP; Shau DN; Staley CA; Roberson JR
    J Arthroplasty; 2021 Jul; 36(7):2364-2370. PubMed ID: 33674164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
    Groff H; Azboy I; Parvizi J
    J Arthroplasty; 2018 Nov; 33(11):3398-3401. PubMed ID: 30017220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
    Gómez-Outes A; Avendaño-Solá C; Terleira-Fernández AI; Vargas-Castrillón E
    Pharmacoeconomics; 2014 Sep; 32(9):919-36. PubMed ID: 24895235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Efficacy and Safety of Aspirin and Rivaroxaban Following Enoxaparin Treatment for Prevention of Venous Thromboembolism after Hip Fracture Surgery.
    Huang Q; Xing SX; Zeng Y; Si HB; Zhou ZK; Shen B
    Orthop Surg; 2019 Oct; 11(5):886-894. PubMed ID: 31663285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
    McCullagh L; Tilson L; Walsh C; Barry M
    Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
    Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
    Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Surgical Site Infection Risk Between Warfarin, LMWH, and Aspirin for Venous Thromboprophylaxis in TKA or THA: A Systematic Review and Meta-Analysis.
    Hughes LD; Lum J; Mahfoud Z; Malik RA; Anand A; Charalambous CP
    JBJS Rev; 2020 Dec; 8(12):e20.00021. PubMed ID: 33347014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban, Enoxaparin, or Aspirin for Thromboprophylaxis.
    Lindquist DE; Stewart DW; Brewster A; Waldroup C; Odle BL; Burchette JE; El-Bazouni H
    Clin Appl Thromb Hemost; 2018 Nov; 24(8):1315-1321. PubMed ID: 29716395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effective Modeling of Thromboembolic Chemoprophylaxis for Total Ankle Arthroplasty.
    Martinazzi BJ; Kirchner GJ; Stauch CM; Lorenz FJ; Manto KM; Bonaddio V; Koroneos Z; Aynardi MC
    Foot Ankle Int; 2022 Oct; 43(10):1379-1384. PubMed ID: 35899685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin.
    Rahman WA; Habsa GH; Al-Mohrej OA; Hammad M; Selim NM; Hammad A
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020938865. PubMed ID: 32700655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA.
    Faour M; Piuzzi NS; Brigati DP; Klika AK; Mont MA; Barsoum WK; Higuera CA
    Clin Orthop Relat Res; 2019 Feb; 477(2):396-402. PubMed ID: 30624322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.
    Dager WE
    Ann Pharmacother; 2012 Jan; 46(1):79-88. PubMed ID: 22202495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty.
    Wilson DG; Poole WE; Chauhan SK; Rogers BA
    Bone Joint J; 2016 Aug; 98-B(8):1056-61. PubMed ID: 27482017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 90-Day Adverse Events Associated With Aspirin and Potent Anticoagulation Use for Venous Thromboembolism Prophylaxis: A Cohort Study of 72,288 Total Knee and 35,142 Total Hip Arthroplasty Patients.
    Singh G; Prentice HA; Winston BA; Kroger EW
    J Arthroplasty; 2023 Aug; 38(8):1602-1612.e1. PubMed ID: 36805118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aspirin for Venous Thromboembolic Prophylaxis Following Total Hip and Total Knee Arthroplasty: An Analysis of Safety and Efficacy Accounting for Surgeon Selection Bias.
    Heckmann ND; Piple AS; Wang JC; Richardson MK; Mayfield CK; Oakes DA; Christ AB; Lieberman JR
    J Arthroplasty; 2023 Jul; 38(7 Suppl 2):S412-S419.e1. PubMed ID: 36870517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.